- Home
- HSII vs RCKT Comparison
HSII vs RCKT Comparison
Compare HSII & RCKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HSII
- RCKT
- Stock Information
- Founded
- HSII 1953
- RCKT 1999
- Country
- HSII United States
- RCKT United States
- Employees
- HSII N/A
- RCKT N/A
- Industry
- HSII Diversified Commercial Services
- RCKT Biotechnology: Pharmaceutical Preparations
- Sector
- HSII Consumer Discretionary
- RCKT Health Care
- Exchange
- HSII Nasdaq
- RCKT Nasdaq
- Market Cap
- HSII 904.3M
- RCKT 764.5M
- IPO Year
- HSII 1999
- RCKT N/A
- Fundamental
- Price
- HSII $42.50
- RCKT $7.18
- Analyst Decision
- HSII Buy
- RCKT Strong Buy
- Analyst Count
- HSII 2
- RCKT 10
- Target Price
- HSII $48.00
- RCKT $44.10
- AVG Volume (30 Days)
- HSII 134.7K
- RCKT 3.2M
- Earning Date
- HSII 05-05-2025
- RCKT 05-08-2025
- Dividend Yield
- HSII 1.42%
- RCKT N/A
- EPS Growth
- HSII N/A
- RCKT N/A
- EPS
- HSII 0.37
- RCKT N/A
- Revenue
- HSII $1,116,954,000.00
- RCKT N/A
- Revenue This Year
- HSII $1.86
- RCKT N/A
- Revenue Next Year
- HSII $3.66
- RCKT N/A
- P/E Ratio
- HSII $115.09
- RCKT N/A
- Revenue Growth
- HSII 6.10
- RCKT N/A
- 52 Week Low
- HSII $29.03
- RCKT $4.55
- 52 Week High
- HSII $49.02
- RCKT $26.98
- Technical
- Relative Strength Index (RSI)
- HSII 62.03
- RCKT 46.92
- Support Level
- HSII $38.53
- RCKT $6.21
- Resistance Level
- HSII $41.12
- RCKT $8.26
- Average True Range (ATR)
- HSII 1.16
- RCKT 0.58
- MACD
- HSII 0.52
- RCKT 0.03
- Stochastic Oscillator
- HSII 99.65
- RCKT 28.05
About HSII Heidrick & Struggles International Inc.
Heidrick & Struggles International Inc is a leadership advisory firm providing executive search and consulting services to businesses and business leaders world wide. The company's operating segments includes the executive search business which operates in the Americas; Europe; Asia Pacific and On-Demand Talent and Heidrick Consulting. It generates maximum revenue from the Americas.
About RCKT Rocket Pharmaceuticals Inc.
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. The Company has one reportable segment related to R&D and commercial readiness of its gene therapies.